Clinical trial
Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With…
NCT00150553 · Validus Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00150553 |
|---|---|
| Title | Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder |
| Official title | A Phase IIIb, Randomized, Double-Blind, Parallel Group Study in Bipolar I Patients to Assess the Efficacy and Safety of SPD417 Administered Once Daily vs Twice Daily in the Treatment of Manic Symptoms |
| Lead sponsor | Validus Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Extended-release carbamazepine |
| Enrollment | 102 |
| Start date | Jan 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Nov 2, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: